This story is part of our October 2024 issue. To subscribe, click here.
Peanut allergies affect around
6.1 million Americans, with cases rising as awareness has grown.
A
2017 study found that peanut allergy had increased 21
percent since 2010. But what if there was a way to eliminate the
genes responsible for peanut allergies?
This is the mission at MyFloraDNA, a Sacramento-based
startup working to democratize access to biotechnology on a
global scale. CEO and co-founder Angel Fernandez spent years
researching plant genetics across Spain, Japan, Australia and the
U.S. One thing was clear: Not all farmers had equal access to
high-tech tools.
“I realized that all the discoveries that we do, they are not
being applied by the small and medium companies,” he says.
“Especially the small and medium farmers.”
This realization led him to launch the company in 2021 with his
childhood friend, Javier Buendia. Initially, they focused on
cannabis, a crop severely affected by viruses and lacking
sufficient research, Fernandez says. Bringing together a team of
scientists who specialize in gene editing, he says, MyFloraDNA
developed the first CRISPR-edited cannabis plant.
From there, Fernandez says, he chose to expand to a crop that
could have a big impact on society and help save lives. This led
to the idea for an allergy-free peanut. How does one create that?
The team’s development process can be divided into three steps:
gene discovery, validation in the lab and field, and eventually,
clinical trials with allergists.
He says the team has identified the genes responsible for the
allergies, but it’s not as simple as pressing a delete button.
There isn’t just one gene — there are many. The team is now
exploring how these genes interact and any potential ripple
effects.
“So, for example, there are six, seven genes,” Fernandez says.
“What happens if I remove all of them? Is that the right thing?
Or should I just remove four and keep three? … The good thing is
our team has a lot of good experience in other crops, so we know
how to navigate that.”
MyFloraDNA is looking to raise $1.3 million through StartEngine,
and has already attracted investors who believe in this work.
Roger Casals, an entrepreneur with 25 years of experience and
five businesses under his belt, invested $100,000 in the company,
about 10 percent of the total raised so far.
In 2021, Fernandez and Buendia reached out to Casals via
LinkedIn. As all three are from Spain, the co-founders wanted
feedback from Casals about how to build a company in the U.S.
Casals appreciated their honesty and humility, and agreed to
meet. The startup also appealed to Casals on a personal level
because he has a daughter with a severe allergy to nuts.
“I understand how frustrating and how limiting it is to have such
a severe allergy,” he says. “You always live in fear. You always
carry your EpiPens. I understand it’s not a majority, but it’s
not nothing.”
The Big Pharma solution has been to introduce more drugs, he
says, which he isn’t interested in. But MyFloraDNA was onto
something innovative. These days, he says, there are a few
cutting edge fields where investment can have a meaningful
impact, including AI, clean energy and quantum computing. Gene
editing is another one.
And as an entrepreneur who started five businesses and admits he
“made a lot of money, but failed on the goal of creating a big
company,” Casals had been looking to create a legacy and make an
impact.
“I saw what they were doing with MyFloraDNA and the CRISPR thing,
which is basically gene editing,” he says. “I said, ‘Hold on,
this is something worth my time, not only my money. So I’m going
to start investing my time with you, being your advisor.’”
His daughter is allergic to tree nuts (not peanuts), but it takes
several years for trees to grow and produce nuts, making it
difficult to know if a genetic modification worked. But peanuts,
as a legume, grow annually. This means you can plant them today
and get results within months about their allergenic properties.
That’s why they started with peanuts.
Once the team confirms the results in the lab, they will bring
the baby plants to the field to grow. After harvesting the
peanuts and raising funds, they will validate that the genes have
been removed. This will be tested for two consecutive harvests,
Fernandez says.
“The next step is going to be to talk to allergy specialists or
immunologists, and start research on or experiment with human
beings,” Fernandez says. “To reach that level, it can take two to
three years.”
–
Stay up to date on innovation in the Capital Region:
Subscribe to the Comstock’s newsletter
today!
